Drug developer jazzed to receive FDA approval for leukemia treatment

Jazz Pharmaceuticals, a drug developer based in Ireland that is in the process of expanding its U.S. presence in Philadelphia, received Food and Drug Administration approval Thursday for its experimental leukemia treatment. The FDA approved Vyxeos as an injectable therapy for adults with two types of acute myeloid leukemia, a rapidly progressing and life-threatening blood cancer. Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals (Nasdaq: JAZZ), said Vyxeos is the first new chemotherapy advance…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news